These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20885974)

  • 21. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
    Lee HJ; Oh SJ; Lee EJ; Chung JH; Kim Y; Ryu JS; Kim SY; Lee SJ; Moon DH; Kim TW
    Cancer Chemother Pharmacol; 2015 May; 75(5):1005-13. PubMed ID: 25776904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
    Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
    J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin--an adjunct antineoplastic therapy--divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging.
    Habibollahi P; van den Berg NS; Kuruppu D; Loda M; Mahmood U
    J Nucl Med; 2013 Feb; 54(2):252-8. PubMed ID: 23376854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Prediction of Radiotherapeutic Efficacy in a Mouse Model of Non-Small Cell Lung Carcinoma Using
    Otani T; Ikushima H; Bando Y; Yamashita M; Kuwahara K; Otsuka H; Kondo K; Miyoshi H
    J Med Invest; 2023; 70(3.4):361-368. PubMed ID: 37940520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET.
    Honndorf VS; Wiehr S; Rolle AM; Schmitt J; Kreft L; Quintanilla-Martinez L; Kohlhofer U; Reischl G; Maurer A; Boldt K; Schwarz M; Schmidt H; Pichler BJ
    Oncotarget; 2016 May; 7(19):28247-61. PubMed ID: 27070087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
    Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
    Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
    Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
    J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.
    Keen H; Pichler B; Kukuk D; Duchamp O; Raguin O; Shannon A; Whalley N; Jacobs V; Bales J; Gingles N; Ricketts SA; Wedge SR
    Mol Imaging Biol; 2012 Jun; 14(3):355-65. PubMed ID: 21761255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.